PRNewswire

Results will be presented at the 66th American Society of Hematology Annual Meeting PHILADELPHIA, Dec. 7, 2024 /PRNewswire/ — Researchers at Children’s Hospital of Philadelphia (CHOP) and the Children’s Oncology Group (COG) announced the results of a Phase 3 study that demonstrate

Phase 3 Study Results Demonstrated Three Year, Disease-Free Survival of 96% THOUSAND OAKS, Calif., Dec. 7, 2024 /PRNewswire/ — Amgen (NASDAQ:AMGN) today announced new data demonstrating that adding BLINCYTO® (blinatumomab) to chemotherapy significantly improves disease-free survival (DFS) in

Magazine made for you.

Featured:

No posts were found for provided query parameters.

Elsewhere: